Responding to COVID-19.    Read More

Products

Factor VII (Recombinant) / Anti-inhibitor

Factor VII products are used to manage acute bleeding or to prevent excessive bleeding as a treatment for patients with hemophilia, acquired inhibitors, or factor deficiency.

Nufactor carries the following F.D.A.-approved
Factor VII Anti-Inhibitors (Congenital and/or Acquired Hemophilia) products:

* denotes that Nufactor does not currently carry this product.

Product
Manufacturer
FDA-Approved Indication
Factor VII (Recombinant)
Product: FEIBA
Manufacturer: Shire
FDA-Approved Indication: Hemophilia A and
Hemophilia B
Product: Hemlibra®
Manufacturer: Genentech
FDA-Approved Indication: Hemophilia A 1
Product: NovoSeven® RT
Manufacturer: Novo Nordisk
FDA-Approved Indication: Hemophilia A and
Hemophilia B
Product: OBIZUR*
Manufacturer: Shire
FDA-Approved Indication: Hemophilia A
 1. HEMLIBRA is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
Click here for patient admission documents.

Nufactor, Inc. is the specialty pharmacy subsidiary of FFF Enterprises, a leading, trusted distributor of plasma products, vaccines and other biopharmaceuticals.

Nufactor
44900 Winchester Road
Temecula, CA 92590

(800) 323-6832

Main Home • Patient Home • Become a Patient • Terms • Privacy Statement • • About • Join Nufactor Team • Contact FFF Enterprises–  ©2019 Nufactor